A leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease.
Location: United States, Colorado, Boulder
Total raised: $6.1M
Investors 2
| Date | Name | Website |
| - | CRG | crglp.com |
| - | Perceptive... | perceptive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.01.2014 | Series E | $6.1M | - |
Mentions in press and media 20
| Date | Title | Description | Source |
| 13.07.2023 | Biodesix Announces Publication of the ORACLE Clinical Utilit... | New publication in PLOS ONE, a journal of the Public Library of Science, reaffirms clinical utility ... | aithority.... |
| 23.11.2022 | Business Business | Boulder’s Biodesix closes $40M stock of... | Biodesix Inc. (Nasdaq: BDSX), a Boulder life-sciences company that specializes in developing tools t... | dailycamer... |
| 09.03.2021 | Biodesix to Report Fourth Quarter and Fiscal 2020 Financial ... | BOULDER, Colo.--(BUSINESS WIRE)--Mar 9, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven ... | oaoa.com/n... |
| 09.07.2019 | Boulder-based Biodesix announces partnership to develop liqu... | Boulder-based lung cancer diagnostic company Biodesix announced Tuesday that it has entered into an ... | dailycamer... |
| 30.06.2019 | Biodesix to buy U.S. lab, lung nodule test from Oncimmune | A U.S.-based diagnostics company is expanding its presence in lung cancer with the acquisition of as... | medcitynew... |
| 28.06.2019 | Biodesix extends its blood-based lung cancer diagnostic port... | Boulder-based Biodesix, Inc. is acquiring a Kansas lab run by Oncimmune Holdings, a global immunodia... | dailycamer... |
| 16.04.2019 | Guardant Health study shows liquid biopsy picking up more mu... | Based on interviews with oncologists, Cannacord analyst Mark Massaro wrote in a note to clients Tues... | medcitynew... |
| 09.07.2018 | Biodesix acquires Seattle-based developer of blood-based lun... | Results of the prospective clinical trial PANOPTIC showed that XL2 was 98 percent effective at disti... | medcitynew... |
| 23.06.2015 | Biodesix Raises Additional $11M in Series E Financing | Biodesix Inc., a Buolder, Co.-based molecular diagnostics company that researches, develops and comm... | finsmes.co... |
| 12.01.2015 | Biodesix Raised Additional $12M in Series E Funding | Biodesix, Inc., a Boulder, Colo.-based molecular diagnostics company that develops and commercialize... | finsmes.co... |
Show more